RenovoRx Statistics
Total Valuation
RenovoRx has a market cap or net worth of $37.84 million. The enterprise value is $32.39 million.
Important Dates
The next estimated earnings date is Thursday, May 14, 2026, after market close.
| Earnings Date | May 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
RenovoRx has 45.05 million shares outstanding. The number of shares has increased by 58.65% in one year.
| Current Share Class | 45.05M |
| Shares Outstanding | 45.05M |
| Shares Change (YoY) | +58.65% |
| Shares Change (QoQ) | +0.03% |
| Owned by Insiders (%) | 3.26% |
| Owned by Institutions (%) | 8.27% |
| Float | 40.75M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 34.91 |
| Forward PS | 11.83 |
| PB Ratio | 5.88 |
| P/TBV Ratio | 7.23 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 28.84 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.02, with a Debt / Equity ratio of 0.04.
| Current Ratio | 4.02 |
| Quick Ratio | 3.65 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -225.62% and return on invested capital (ROIC) is -144.49%.
| Return on Equity (ROE) | -225.62% |
| Return on Assets (ROA) | -92.60% |
| Return on Invested Capital (ROIC) | -144.49% |
| Return on Capital Employed (ROCE) | -195.83% |
| Weighted Average Cost of Capital (WACC) | 10.90% |
| Revenue Per Employee | $66,059 |
| Profits Per Employee | -$656,941 |
| Employee Count | 17 |
| Asset Turnover | 0.14 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -15.15% in the last 52 weeks. The beta is 1.22, so RenovoRx's price volatility has been higher than the market average.
| Beta (5Y) | 1.22 |
| 52-Week Price Change | -15.15% |
| 50-Day Moving Average | 0.95 |
| 200-Day Moving Average | 1.03 |
| Relative Strength Index (RSI) | 35.01 |
| Average Volume (20 Days) | 321,799 |
Short Selling Information
The latest short interest is 470,946, so 1.05% of the outstanding shares have been sold short.
| Short Interest | 470,946 |
| Short Previous Month | 594,804 |
| Short % of Shares Out | 1.05% |
| Short % of Float | 1.16% |
| Short Ratio (days to cover) | 0.96 |
Income Statement
In the last 12 months, RenovoRx had revenue of $1.12 million and -$11.17 million in losses. Loss per share was -$0.32.
| Revenue | 1.12M |
| Gross Profit | 796,000 |
| Operating Income | -12.01M |
| Pretax Income | -11.17M |
| Net Income | -11.17M |
| EBITDA | -12.01M |
| EBIT | -12.01M |
| Loss Per Share | -$0.32 |
Full Income StatementBalance Sheet
The company has $7.02 million in cash and $212,000 in debt, with a net cash position of $6.81 million or $0.15 per share.
| Cash & Cash Equivalents | 7.02M |
| Total Debt | 212,000 |
| Net Cash | 6.81M |
| Net Cash Per Share | $0.15 |
| Equity (Book Value) | 5.42M |
| Book Value Per Share | 0.15 |
| Working Capital | 5.93M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$10.97 million and capital expenditures -$2,000, giving a free cash flow of -$10.98 million.
| Operating Cash Flow | -10.97M |
| Capital Expenditures | -2,000 |
| Depreciation & Amortization | 2,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -10.98M |
| FCF Per Share | -$0.24 |
Full Cash Flow StatementMargins
| Gross Margin | 70.88% |
| Operating Margin | -1,069.46% |
| Pretax Margin | -994.48% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
RenovoRx does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -58.65% |
| Shareholder Yield | -58.65% |
| Earnings Yield | -28.49% |
| FCF Yield | -28.00% |
Analyst Forecast
The average price target for RenovoRx is $8.25, which is 882.14% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $8.25 |
| Price Target Difference | 882.14% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 77.61% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
RenovoRx has an Altman Z-Score of -5.7 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -5.7 |
| Piotroski F-Score | 2 |
